This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sousa, M. M. Articles by Saraiva, M. J. Search for Related Content PubMed PubMed Citation Articles by Sousa, M. M. Articles by Saraiva, M. J.

(American Journal of Pathology. 2002;161:1935-1948.)
© 2002 American Society for Investigative Pathology

Animal Model

Evidence for Early Cytotoxic Aggregates in Transgenic Mice for Human Transthyretin Leu55Pro

Mónica Mendes Sousa^*, Rui Fernandes^*, Joana Almeida Palha^*, Ana Taboada^*, Paulo Vieira and Maria João Saraiva^*

From the Amyloid Unit,^* Instituto de Biologia Molecular e Celular, Porto; the Instituto Gulbenkian de Ciência, Oeiras; and the Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal

Familial amyloidotic polyneuropathy (FAP) is a lethal autosomal dominant disorder characterized by systemic extracellular deposition of transthyretin (TTR) amyloid fibrils. Several groups have generated transgenic mice carrying human TTR Val30Met, the most common mutation in FAP. To study amyloidogenicity and cytotoxicity of different TTRs, we produced transgenic mice expressing human TTR Leu55Pro, one of the most aggressive FAP-related mutations. TTR deposition and presence of amyloid fibrils was investigated and compared to animals carrying the human TTR Val30Met gene kept under the same conditions. Deposition in a C57BL/6J background (TTR-Leu55Pro mice) and in a TTR-null background [TTR-Leu55Pro X TTR-knockout (KO) mice] was compared. Animals in a C57BL/6J background presented early (1 to 3 months) nonfibrillar TTR deposition but amyloid was absent. In a TTR-null background, presence of amyloid fibrils was detected starting at 4 to 8 months with a particular involvement of the gastrointestinal tract and skin. This data suggested that TTR homotetramers are more prone to fibril formation than TTR murine wild-type/human mutant heterotetramers. The nature of the deposited material was further investigated by immunocytochemistry. Both amorphous aggregates and small TTR fibrils were present in TTR-Leu55Pro X TTR-KO transgenics. We observed that these TTR deposits mimic the toxic effect of TTR deposits in FAP: animals with TTR deposition, present approximately twofold increased levels of nitrotyrosine in sites related to deposition. The TTR-Leu55Pro X TTR-KO mice here described are an important tool for the dual purpose of investigating factors involved in amyloidogenesis and in cytotoxicity of deposited TTR.

This article has been cited by other articles:

				G. Zhao, Z. Li, K. Araki, K. Haruna, K. Yamaguchi, M. Araki, M. Takeya, Y. Ando, and K.-i. Yamamura Inconsistency between hepatic expression and serum concentration of transthyretin in mice humanized at the transthyretin locus Genes Cells, December 1, 2008; 13(12): 1257 - 1268. [Abstract] [Full Text] [PDF]

				R. E. Steward, R. S. Armen, and V. Daggett Different disease-causing mutations in transthyretin trigger the same conformational conversion Protein Eng. Des. Sel., March 1, 2008; 21(3): 187 - 195. [Abstract] [Full Text] [PDF]

				N. Reixach, T. R. Foss, E. Santelli, J. Pascual, J. W. Kelly, and J. N. Buxbaum Human-Murine Transthyretin Heterotetramers Are Kinetically Stable and Non-amyloidogenic: A LESSON IN THE GENERATION OF TRANSGENIC MODELS OF DISEASES INVOLVING OLIGOMERIC PROTEINS J. Biol. Chem., January 25, 2008; 283(4): 2098 - 2107. [Abstract] [Full Text] [PDF]

				I. Cardoso and M. J. Saraiva Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model FASEB J, February 1, 2006; 20(2): 234 - 239. [Abstract] [Full Text] [PDF]

				H. Koike, K. Misu, M. Sugiura, M. Iijima, K. Mori, M. Yamamoto, N. Hattori, E. Mukai, Y. Ando, S. Ikeda, et al. Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy Neurology, July 13, 2004; 63(1): 129 - 138. [Abstract] [Full Text] [PDF]

				M. A. Liz, C. J. Faro, M. J. Saraiva, and M. M. Sousa Transthyretin, a New Cryptic Protease J. Biol. Chem., May 14, 2004; 279(20): 21431 - 21438. [Abstract] [Full Text] [PDF]

				T. Korenaga, X. Fu, Y. Xing, T. Matsusita, K. Kuramoto, S. Syumiya, K. Hasegawa, H. Naiki, M. Ueno, T. Ishihara, et al. Tissue Distribution, Biochemical Properties, and Transmission of Mouse Type A AApoAII Amyloid Fibrils Am. J. Pathol., May 1, 2004; 164(5): 1597 - 1606. [Abstract] [Full Text] [PDF]

				Y. Takaoka, M. Ohta, K. Miyakawa, O. Nakamura, M. Suzuki, K. Takahashi, K.-i. Yamamura, and Y. Sakaki Cysteine 10 Is a Key Residue in Amyloidogenesis of Human Transthyretin Val30Met Am. J. Pathol., January 1, 2004; 164(1): 337 - 345. [Abstract] [Full Text] [PDF]